Biofourmis is a digital therapeutics company founded in 2015 with the vision to empower personalized predictive care by delivering precise interventions at the right time to improve outcomes. Below is our recent interview with Kuldeep Singh Rajput, the Founder and CEO of Biofourmis:
Q: Could you provide our readers with a brief introduction to Biofourmis?
A: Biofourmis solutions are deployed world-wide with some of the world’s most respected healthcare providers, ministries of health and pharmaceutical companies—collaborators like Novartis, Chugai, Brigham and Women’s Hospital, and Mayo Clinic that use our clinically validated, predictive platform to more precisely manage, intervene, and treat chronic patients in a way that’s proactive and liberating. That’s the power of personalized predictive care.
Currently, Biofourmis’s modular digital therapeutic platforms is deployed across multiple disease areas to proactively optimize management of heart failure, respiratory conditions, cancer, and infectious disease management.
Q: Could you explain the function and advantages of Biofourmis compared to other available healthcare companies?
A: Biofourmis is the pioneer in personalized predictive care by bringing together continuous monitoring of 20+ physiological signals using clinical grade Everion wearable device and leveraging AI/ML tools to predict and detect disease or adverse event before it happens.
As compared to many other digital heath companies, Biofourmis’s solutions are built on the strong foundation of data science, clinical trial evidence and regulatory clearances. Also, Biofourmis solutions have been co-created with patients, caregivers and HCPs, resulting in the simplicity and ease of use that has enabled industry leading compliance rate and adoption across patients of various age groups.
Q: How did the business develop?
A: Biofourmis was founded 2015 with the vision to predict disease before it happens.
With this vision, Biofourmis developed a modular and device-agnostic platform that was initially focused on cardiovascular disease area (e.g. heart failure, cardiac arrhythmias) and later rapidly expanded into pain management as well as cancer management.
Over the last 12 months, Biofourmis has grown very rapidly, making several acquisitions that included Biovotion (with industry leading CE marked Everion wearable device) and Gaido (innovative solution for cancer management). Also, Biofourmis launched several Pill+ innovative solutions and co-development of combo therapies in partnerships with leading pharma companies in the world (e.g. Novartis, Chugai).
With Covid-19 pandemic, Biofourmis leveraged its highly modular platform to rapidly develop a solution to monitor and manage infectious diseases (e.g. Covid-19) and deployed the solutions world-wide in partnerships with the leading hospital systems, researchers and Ministries of health (e.g. Ministry Of Health, Singapore).
Q: Who would be your ideal client and why?
A: Biofourmis partners and delivers unique value proposition for all key stakeholders of health-care eco-system, including patients, health systems, payers, pharma and regulators. Among the health systems, ideal client is the one that shares the vision to leverage technology innovations for improving health outcomes while reducing the costs. Among the pharma, we partner with companies that aspire to innovate beyond the pill/molecule for improving outcomes.
Q: What can we expect from Biofourmis in the future?
A: In the near future, Biofourmis will be launching our intelligent remote monitoring solutions with several leading health systems, payers and pharma companies. In the long term. Biofourmis will advance its pipeline and launch several digital therapeutics, as mono or combo therapies (in combination with pharma therapies), across the disease areas with significant unmet needs such as heart failure, cancer, pain management etc.